Economic burden of severe asthma treatment: A real-life study

Papi, 2018, Asthma, Lancet., 391, 783, 10.1016/S0140-6736(17)33311-1 Rehman, 2018, Prevalence of asthma and its management: a review, J Pakistan Med Assoc, 68, 1823 Wang, 2016, Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet, 388, 1459, 10.1016/S0140-6736(16)31012-1 Forno, 2015, Asthma in Latin America, Thorax, 70, 898, 10.1136/thoraxjnl-2015-207199 García-Sancho, 2012, Prevalencia y riesgos asociados con pacientes adultos con asma de 40 años o más de la Ciudad de México: estudio de base poblacional, Salud Publica Mex, 54, 425, 10.1590/S0036-36342012000400013 Cisneros Serrano, 2015, Normativa sobre asma grave no controlada, Arch Bronconeumol, 51, 235, 10.1016/j.arbres.2014.12.007 Lötvall, 2011, Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome, J Allergy Clin Immunol, 127, 355, 10.1016/j.jaci.2010.11.037 Enilari, 2019, The global impact of asthma in adult populatio, Ann Glob Heal, 85, 1 López Tiro, 2015, Real life study of three years omalizumab in patients with difficult-to-control asthma, Allergol Immunopathol, 43, 120, 10.1016/j.aller.2013.11.008 Ramsahai, 2019, Mechanisms and management of asthma exacerbations, Am J Respir Crit Care Med, 199, 423, 10.1164/rccm.201810-1931CI Anderson, 2019, Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic?, Ann Allergy Asthma Immunol, 122, 367, 10.1016/j.anai.2019.01.018 Miranda, 2020, The effectiveness of omalizumab in the control of severe uncontrolled asthma in Latin America. An exploratory systematic review and meta-analysis, Rev Alerg Mex, 67, 19, 10.29262/ram.v67i1.701 Almonacid-Sánchez, 2019, Análisis económico de las terapias biológicas en asma grave, Farm Hosp, 43, 175 Agache, 2020, Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, Allergy Eur J Allergy Clin Immunol, 75, 1023, 10.1111/all.14221 GINA. Global Strategy for Asthma Management and Prevention; 2021. www.ginasthma.org. Hurst, 1999, The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List, Clin Cardiol, 22, 385, 10.1002/clc.4960220604 Burnham, 2004, Multimodel inference understanding AIC and BIC in model selection, Socio Methods Res, 33, 261, 10.1177/0049124104268644 Team TRDC. R: A language and environment for statistical computing. Published online 2008:2673. Nurmagambetov, 2017 Lee, 2020, Socioeconomic burden of disease due to asthma in South Korea, Asia Pac J Publ Health, 32, 188, 10.1177/1010539520920524 Bedouch, 2012, Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study, PLoS One, 7, 10.1371/journal.pone.0050949 Accordini, 2013, The cost of persistent asthma in Europe: an international population-based study in adults, Int Arch Allergy Immunol, 160, 93, 10.1159/000338998 Costa, 2018, Estimated cost of asthma in outpatient treatment: a real-world study, Rev Saude Publica, 52, 1 Farne, 2017, Anti-IL5 therapies for asthma, Cochrane Database Syst Rev, 2017 Martínez-Moragón, 2019, Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice, Farm Hosp, 43, 101 Entrenas Costa, 2019, Economic impact and clinical outcomes of omalizumab add-on therapy for patients with severe persistent asthma: a real-world study, PharmacoEconomics - Open, 3, 333, 10.1007/s41669-019-0117-4 Karen, 2019, Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018, Expet Rev Clin Immunol, 15, 553, 10.1080/1744666X.2019.1574571 Campisi, 2020, Adherence to omalizumab : a multicenter " real-world " study, World Allergy Organ J, 13, 100103, 10.1016/j.waojou.2020.100103 Reibman, 2021, Clinical and economic burden of severe asthma among US patients treated with biologic therapies, Ann Allergy Asthma Immunol, 127, 318, 10.1016/j.anai.2021.03.015 Gaffin, 2022, The role of comorbidities in difficult-to-control asthma in adults and children, World Allergy Organ J, 10, 397 Sullivan, 2007, Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma, Allergy Eur J Allergy Clin Immunol, 62, 126, 10.1111/j.1398-9995.2006.01254.x Ivanova, 2012, Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma, J Allergy Clin Immunol, 129, 1229, 10.1016/j.jaci.2012.01.039 Inoue, 2019, A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan, NPJ Prim Care Respir Med, 29, 10.1038/s41533-019-0128-8 Flórez-Tanus, 2018, Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis 11 Medical and Health Sciences 1117 Public Health and Health Services, World Allergy Organ J, 11, 26, 10.1186/s40413-018-0205-4 Zeiger, 2016, Utilization and costs of severe uncontrolled asthma in a managed-care setting, J Allergy Clin Immunol Pract, 4, 120, 10.1016/j.jaip.2015.08.003 García-Mochón, 2019, Evaluación económica y análisis de impacto presupuestario de mepolizumab en asma eosinofílica refractaria grave, Farm Hosp, 43, 187